e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
R. Shrimanker (Bristol, United Kingdom)
Source:
International Congress 2017 – Asthma management
Session:
Asthma management
Session type:
Thematic Poster
Number:
3971
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Shrimanker (Bristol, United Kingdom). Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. 3971
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA)
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype
Source: International Congress 2016 – Asthma management
Year: 2016
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Severe asthma exacerbations with eosinophilic bronchitis: a randomized controlled comparison of the anti-inflammatory effects of deflazacort
vs.
prednisone
Source: Eur Respir J 2006; 28: Suppl. 50, 441s
Year: 2006
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Year: 2020
Exacerbations of severe asthma in patients treated with mepolizumab
Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018
Year: 2018
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Utility of aerosolized budesonide therapy in acute moderate exacerbations of asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 283s
Year: 2003
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Source: International Congress 2017 – Asthma management
Year: 2017
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Mepolizumab in real-life treatment of severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept